Earnings Releases·Nov 4, 2026, 4:15 PM ET

Cytek Biosciences — Third Quarter 2026 Earnings Summary

Total revenue rose 2% year-over-year to $53.2 million, while GAAP gross margin improved 590 basis points to 59% and recurring revenue share increased to 36% of total revenue.
The company narrowed its full-year 2026 revenue guidance range to $208 million–$211 million, maintaining the midpoint and citing expectations for a strong year-end finish.
Operating loss narrowed to $8.4 million from $9.2 million in the prior year period, though adjusted EBITDA declined to $0.7 million from $2.5 million.
Strategic highlights include a 12% U.S. revenue growth, an installed base expansion to 4,073 units, and a favorable jury verdict on three of four patent claims, with the company pursuing further legal remedies.